The value of S-phase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the Australian setting

Pathology

Volumn 31, Issue 2, 1999, Pages 90-94

  Wong, Sue W J ^a   Rangan, Anna M ^b   Bilous, A Michael ^b   Boyages, John ^b   Gebski, Val ^b   Benson, Elizabeth M ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b NONE

Author keywords

DNA flow cytometry; DNA ploidy; Node negative breast cancer; S phase fraction

Indexed keywords

HORMONE RECEPTOR;

ADULT; AGED; ANEUPLOIDY; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; DEVICE; DIPLOIDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HISTOGRAM; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; OUTCOMES RESEARCH; PLOIDY; PROGNOSIS; TUMOR VOLUME;

EID: 0032987507     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/003130299105241     Document Type: Article

References (33)

1. 1. Hedley DW. Breast cancer. In: Bauer KD, Duque RE, Shankey VT, editors. Clinical flow cytometry: principles and applications. Baltimore: Williams and Wilkins, 1993; Chapter 14.
2. 2. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 1206-19.
3. 3. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Eng J Med 1989; 320: 627-33.
4. 4. Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, et al. Prognostic significance of S-Phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1992; 10: 428-32.
5. 5. Ewers S, Langstorm E, Baldetorp B, Killander D. Flow Cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry 1984; 5: 408-19.
6. 6. O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Rubens RD, Richards MA. Node-negative breast cancer: prognostic subgroups defined by tumour size and flow cytometry. J Clin Oncol 1990; 8: 2040-6.
7. 7. Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Ferno M, et al. Indicators of prognosis in node-negative breast cancer. N Eng J Med 1990; 322: 1045-53.
8. 8. Stal O, Dufmats M, Hatscheck T, Carstensen J, Klintenberg C, et al. S-Phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 1993; 11: 1717-22.
9. 9. Yuan J, Hennessy C, Givan AL, Corbett IP, Henry JA, Sherbert GV, et al. Predicting outcome for patients with node negative breast cancer: a comparative study of the value of flow cytometry and cell image analysis for determination of DNA ploidy. Br J Cancer 1992; 65: 461-5.
10. 10. Dressler LG, Seamer LC, Owens MA, et al. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988; 61: 420-7.
11. 11. Winchester DJ, Duda RB, August CZ, Goldschmidt RA, Wruk DM, et al. The importance of DNA flow cytometry in node-negative breast cancer. Arch Surg 1990; 125: 886-9.
12. 12. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry. 1993; 14: 482-5.
13. 13. Hedley WD, Shankey TV, Wheeless LL. DNA cytometry consensus conference. Cytometry 1993; 14: 471.
14. 14. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, editors. Diagnostic Histopathology of the Breast. Edinburgh, Churchill Livingstone, 1987; 300-311.
15. 15. Bilous AM, Tyler JP, Toppila M, et al. Whither cytosolic estrogen receptor assays? A comparison of commercially available kits for estrogen receptor assay. Pathology 1987; 19: 223-8.
16. 16. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
17. 17. Bauer KD. Rapid Propidium Iodide-Based DNA Content Staining Method. In: 3rd Australian Flow Cytometry Methods Course manual, Melbourne, 1993
18. 18. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, et al. Guidelines for Implementation of Clinical DNA Cytometry. Cytometry 1993; 14: 472-7.
19. 19. Korn EL. Censoring distributions as a measure of follow-up in survival data analysis. Stat in Med 1986; 5: 255-60.
20. 20. McDivitt RW, Stone KR, Craig RB, Meyer JS. A proposed classification of breast cancer based on kinetic information. Cancer 1986; 57: 269-76.
21. 21. Tubiana M, Pejovie MH, Chavaudra N, et al. The long-term significance of thymidine labelling index in breast cancer. Int J Cancer 1984; 33: 441-5.
22. 22. Seamer L, Dressler LG, Schimke R. Comparison of S-phase estimation using BrdU incorporation versus a para1/para2 modelling system. Cytometry 1988. Proceedings of the XIII International Meeting of the Society for Analytical Cytology (Suppl 2).
23. 23. Merkel DE, Winchester DJ, Goldschmidt RA, et al. DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer. Cancer 1993; 1926-32.
24. 24. Kallioniemi OP, Blanco G, Alavaikko M, Hietanen T, Mattilia J, Lauslahti K, et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. Cancer 1988; 62: 2183-219.
25. 25. Ottesen GL, Christensen IL, Larson JK, Kerndrup GB, Hansen B, et al. DNA aneuploidy in early breast cancer. Br J Cancer 1995; 72: 832-9.
26. 26. Witzig TE, Ingle JN, Cha SS, Schaid DJ, Tabery RL, et al. DNA ploidy and the percentage of cells in S-Phase as prognostic factors for women with lymph node-negative breast cancer. Cancer 1994; 74: 1752-61.
27. 27. Bosari S, Lee AKC, Tahan SR, Figoni MAT, Wiley BD, et al. DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma. Cancer 1992; 70: 1943-50.
28. 28. Toikkanen S, Joensus H, Klemi P. The prognostic significance of nuclear DNA content in invasive breast cancer: a study with long-term follow-up. Br. J Cancer 1989; 60: 693-700.
29. 29. Thorud E, Fossa SD, Vaage S, Kaalhus O, Knudsen OS, Bormer O, et al. Flow cytometry DNA pattern in relation to clinical and histopathologic characteristics. Cancer 1986; 57: 808-11.
30. 30. Kallioniemi OP, Blanco G, Alavaikko M, et al. Tumour DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer 1987; 5: 637-42.
31. 31. Cornelisse CJ, Van de Velde RJ, Casper C, et al. DNA ploidy and survival in breast cancer patients. Cytometry 1987; 8: 225-34.
32. 32. Muss HB, Kute TE, Case LD, Smith R, Booher C, Long R, et al. The relation of flow cytometry to clinical and biologic characteristics in women with node-negative primary breast cancer. Cancer 1989; 64: 1894-900.
33. 33. Dressler LG. DNA flow cytometry measurements as surrogate endpoints in chemoprevention trials: clinical, biological, and quality control considerations. J Cell Biochem 1993; 176: 212-8.